Thank you This live web event has ended. Thank you for attending. Contributors Mark Sommerville, Ph.D. (AstraZeneca/Pearl Therapeutics) Mark obtained his BS in biochemistry from Virginia Tech, and a masters degree in pharmacology from Case Western Reserve. After working as an analytical organic chemist and bioanalytical chemist for 10 years, he found his niche in pharmaceutical formulation. After a doctorate at UNC Chapel Hill with Tony Hickey, he worked at GlaxoSmithKline for 8 years in MDI formulation, making contributions in the areas of MDI science, foreign particulate analysis, extractables and leachables characterization, spray drying, and novel excipients. After GSK Mark joined Pearl Therapeutics in 2008, where he has worked in various areas including analytical method development, valve conditioning procedures, valve design, formulation development, extractables and leachables, CT analysis, electrostatics, and foreign particulate matter evaluation. He is the SEM lead and consults across departments on a variety of topics.